Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
نویسندگان
چکیده
منابع مشابه
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Trastuzumab with a taxane as first-line therapy is now the standard of care for patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (MBC). The search for additional and more effective trastuzumab-based therapies continues. Novel combinations of trastuzumab with chemotherapeutic agents, including vinorelbine, gemcitabine, and capecitabine, and hormona...
متن کاملGene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.
PURPOSE Therapeutic monoclonal antibody is increasingly applied in many clinical applications, although complicated technologies and high cost still limit their wide applications. To obtain the sustained serum antibody concentration with one single injection and lower the cost of antibody protein therapy, an adenovirus-mediated full-length antibody gene therapy was developed. EXPERIMENTAL DES...
متن کاملSevere cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Immune checkpoint inhibitors such as ipilimumab and targeted BRAF inhibitors have dramatically altered the landscape of melanoma therapeutics over the past few years. Agents targeting the programmed cell death-1/ligand (PD-1/PD-L1) axis are now being developed and appear to be highly active clinically with favorable toxicity profiles. We report two patients with BRAF V600E mutant melanoma who w...
متن کاملIs adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?
BACKGROUND In light of clinical uncertainty and the high acquisition costs of trastuzumab, we examined the value for money associated with concurrent or sequential trastuzumab in women with HER-2/neu-positive breast cancer with small node-negative tumours (T1bN0). MATERIALS AND METHODS A probabilistic economic model was developed to estimate the likelihood of adjuvant trastuzumab meeting a $1...
متن کاملHER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
PURPOSE Trastuzumab therapy has been shown to benefit metastatic breast cancer patients whose tumors exhibit HER-2 protein overexpression or gene amplification. Several tests of varying accuracy and cost are available to identify candidates for trastuzumab. We estimated the cost-effectiveness of alternative HER-2 testing and trastuzumab treatment strategies. PATIENTS AND METHODS We performed ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Genes & Diseases
سال: 2017
ISSN: 2352-3042
DOI: 10.1016/j.gendis.2017.07.007